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Utilization of NGs technologies 
to investigate transcriptomic 
and epigenomic mechanisms in 
trastuzumab resistance
Miguel Nava1,2, Pranabananda Dutta1, Robin Farias-eisner2, Jaydutt V. Vadgama1,2 & 
Yanyuan Wu1,2
NGS (Next Generation Sequencing) technologies allows us to determine key gene expression signatures 
that correlate with resistance (and responsiveness) to anti-cancer therapeutics. We have undertaken 
a transcriptomic and chromatin immunoprecipitation followed by sequencing (ChIP-seq) approach 
to describe differences in gene expression and the underlying chromatin landscape between two 
representative HER2+ cell lines, one of which is sensitive (SKBR3) and the other which is resistant 
(JIMT1) to trastuzumab. We identified differentially expressed genes (DEGs) and differentially 
expressed transcripts (DETs) between SKBR3 and JIMT1 cells. Several of the DEGs are components of 
the Polycomb Repressing Complex 2 (PRC2), and they are expressed higher in JIMT1 cells. In addition, 
we utilized ChIP-seq to identify H3K18ac, H3K27ac and H3K27me3 histone modifications genome-
wide. We identified key differences of H3K18ac and H3K27ac enrichment in regulatory regions, found a 
correlation between these modifications and differential gene expression and identified a transcription 
factor binding motif for LRF near these modifications in both cell lines. Lastly, we found a small 
subset of genes that contain repressive H3K27me3 marks near the gene body in SKBR3 cells but are 
absent in JIMT1. Taken together, our data suggests that differential gene expression and trastuzumab 
responsiveness in JIMT1 and SKBR3 is determined by epigenetic mechanisms.
HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers1. Prior to the clinical approval of 
trastuzumab, patients diagnosed with HER2+ breast cancer exhibited the worst prognosis and highest mortality2. 
Monoclonal antibody therapies, such as trastuzumab and pertuzumab, and receptor tyrosine kinase inhibitors, 
such as Lapatinib, directed against the Human Epidermal Receptors (HER) have vastly improved HER2+ breast 
cancer patient outcomes2,3. Nonetheless, resistance to therapies is a clinical reality. It is estimated that 60–80% of 
HER2+ breast cancer patients treated with trastuzumab develop resistance1.
HER2 is a classical receptor tyrosine kinase (RTK) and its signal transduction potential is realized by heterod-
imerization with other ligand bound HER family members, such as EGFR/HER14–6. Primary or acquired resist-
ance of HER2+ breast cancer tumors to therapies, including trastuzumab, has been a major challenge for clinical 
management of this disease. Resistance to trastuzumab involves a myriad of mechanisms including, but not lim-
ited to: intrinsic alternations in HER2 receptor (e.g. deletions of the regions coding the trastuzumab binding site), 
loss of antibody-dependent cell-mediated cytotoxicity (ADCC), intracellular alterations in HER2 downstream 
signaling, and crosstalk between receptors and signaling pathways leading to activation of other HER family 
receptors, such as EGFR7.
SKBR3 cells were isolated from pleural effusion cells of a Caucasian female patient who had undergone several 
rounds of treatment with radiation8. SKBR3 cells are sensitive to trastuzumab, but trastuzumab resistant SKBR3 
cells have been generated by us and others in a laboratory setting9,10. We previously demonstrated that SKBR3 (lab 
generated) trastuzumab-resistant cells expressed higher levels of WNT3 and EGFR than parental cells9. JIMT1 
cells, which are intrinsically resistant to trastuzumab and are also from pleural effusion cells from a Caucasian 
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female11, also expressed higher levels of WNT3 but not EGFR compared to SKBR3 cells9 (data not shown). Some 
groups have conducted comparisons between SKBR3 and JIMT1 cells and have used systems biology approach12 
which uses established sub-pathway identification and network permutation method. They identified 32 upreg-
ulated KEGG sub-pathway genes that were common to trastuzumab resistant cells versus trastuzumab sensitive 
cells. The network consisted of 4502 sub-pathways. Another excellent review byMartin-Castillo et al.13 suggest 
interesting roles for Cancer Stem Cell (CSC) and non-Cancer Stem Cells (non-CSC) within HER2-overexpressing 
breast carcinomas. They suggest that it is critical to understand the structural interactions between CSC and 
non-CSC for trastuzumab-based treatment decisions in the clinic. The authors have discussed extensively the 
biological significance of CSC features and the EMT on the molecular effects and efficacy of trastuzumab in 
HER2-positive breast cancer cells. They have also focused on the genetic heterogeneity that differentiates 
trastuzumab-responders from non-responders in terms of CSC cellular states.
In addition to these approaches, we suggest that the chromatin landscape needs to be investigated in these 
cell lines (SKBR3, JMT1 and others) to determine how the epigenome might contribute to observations made at 
the level of gene expression. Therefore, we conducted a transcriptomic and ChIP-seq interrogation of JIMT1 and 
SKBR3 cells to determine differential gene expression and epigenomic differences.
Results
Differential gene expression utilizing RNA-seq in JIMT1 and SKBR3 cells. We prepared RNA 
from exponentially growing JIMT1 and SKBR3 cells in biological replicates and conducted RNA-seq. In total, 
we obtained over 70 million reads that passed quality filters for both replicates (Table 1). Total reads were similar 
in number between JIMT1 and SKBR3 (Table 1). Only transcripts and genes with an FPKM > 0.5 for both cell 
lines were analyzed further. We utilized Cufflinks14 to determine gene and transcript expression and generated 
lists containing genes and transcripts that differed by 2-fold between JIMT1 and SKBR3 cells (Supplementary 
datasets). We added further stringency to our data by also compiling data sets for those genes and transcripts that 
were differentially expressed (DE) 2-fold or more and had a p-value less than 0.05 (Fig. 1a). In total, over 6000 
transcripts were DE 2-fold or more, but only ~2800 passed the statistical threshold (Supplementary datasets). On 
the other hand, ~4100 genes were DE 2-fold or more and ~3200 of those passed the statistical threshold (Fig. 1a 
JIMT1 SKBR3
Rep #1 34,429,857 38,280,766
Rep #2 39,205,022 38,392,607
total reads 73,634,879 76,673,373
passed filters 70,689,484 72,839,704
Table 1. RNA-seq reads of replicates. Reads reported from Illumina HiSeq3000 instrument for replicates and 
those passing default quality filters.
Figure 1. RNA-seq results and Gene Ontology (GO) in top DEGs. (a) DETs and DEGs log2 ratios of (Fragments 
Per Kilobase of transcript per Million mapped reads) FPKMs (JIMT1/SKBR3) meeting indicated criteria. 
Statistical testing was conducted by Cufflinks. (b) Three CD44 DETs that were DE at least 2-fold in JIMT1 
relative to SKBR3 cells and their associated p-values as reported by Cufflinks for replicates. CD44 DE in JIMT1 
and SKBR3 cells. (c) Gene ontology (GO) terms for top DE genes determined by DAVID15. Only p-values (as 
reported by DAVID) less than 0.05 are shown. (d) Two-tailed t-test of top-50 genes shown in (c) for each cell line.
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and Supplementary datasets). As an example of one of the well-known differentially expressed genes (DEGs) 
between JIMT1 and SKBR3 cells, we investigated CD44 differentially expressed transcripts (DETs)13. Three CD44 
transcripts were DE 2-fold or more, but according to Cufflinks, only one of them (NM 001001389) was statis-
tically significant, even though the average difference was 150-fold between JIMT1 and SKBR3 (Fig. 1b). CD44 
gene expression was statistically significant (p-value < 0.01) with 150-fold higher levels in JIMT1 compared to 
SKBR3 cells (Fig. 1b).
Gene ontology (GO) of DEGs between JIMT1 and SKBR3. We determined the GO of the top-50 DEGs 
with higher expression in JIMT1 using DAVID15 (Fig. 1c). On average, gene expression differed ~45-fold between 
the top-50 DEGs (Fig. 1d). Interestingly, the top-50 DEGs in JIMT1 are involved in cell motion, cell motility 
and cell migration (Fig. 1c). Examples of these genes includes several of the Annexin gene family, ANXA1, 
ANXA8L1 and ANXA8L2, as well as genes that encode extracellular matrix functioning proteins, MSN, KRT5, 
ITGA6, SERPINE1 and TIMP1 (Supplementary datasets). The top-50 DEGs with higher expression in SKBR3 
are involved in excretion, regulation of cellular proliferation, and locomotory behavior (Fig. 1c). Examples of 
these genes includes KRT81, ANXA2, S100A8, S100A9, MUC1, ID2 and KLF2 (Supplementary datasets). We also 
determined the most highly expressed genes in each cell line and determined their GO (Supplementary Fig. 1). 
These genes are different than the DEGs described above and only differed by ~3.5-fold between cell lines, indi-
cating that these genes are highly expressed in both cell lines. The most highly expressed genes in JIMT1 cells are 
involved in the regulation of metabolism, cytoskeletal organization, and maintenance of protein localization. On 
the other hand, the most highly expressed genes in SKBR3 cells are involved in metabolism, redox reactions, and 
nucleus organization (Supplementary Fig. 1). We subjected the DEGs to Gene Set Enrichment Analysis (GSEA) 
(Supplementary Fig. 2). The analysis showed that 4896/9714 gene sets were upregulated in the JIMT1 pheno-
type compared to SKBR3. Among those, 257 gene sets were significant at FDR < 0.05 with 513 gene sets signif-
icantly enriched at nominal p-value < 0.01 and 1061 gene sets significantly enriched at nominal p-value < 0.05 
(Supplementary Table 1).
Global profiles for H3K18ac and H3K27ac in JIMT1 and SKBR3 cells. In order to investigate the 
underlying chromatin landscape and to determine whether chromatin regulation could explain differential gene 
expression between JIMT1 and SKBR3 cells, we conducted ChIP-seq for H3K18ac and H3K27ac. We decided to 
specifically assay H3K18ac and H3K27ac enrichment because (1) they are marks that are exclusively catalyzed 
by co-activator paralogs P300/CBP16, (2) these marks are enriched in euchromatic regions17, (3) these marks 
increase following activation18, and (4) H3K27ac is a marker of super-enhancers19. Each ChIP for H3K18ac and 
H3K27ac replicate had over 20 million reads, but altogether each condition had over 60 million reads that passed 
quality filters (Table 2).
JIMT1 and SKBR3 had similar numbers of H3K18ac peaks (Fig. 2a). Approximately 40% of H3K18ac peaks 
and 45% of H3K27ac were shared between JIMT1 and SKBR3 cells. SKBR3 had ~17% more H3K27ac peaks than 
JIMT1 cells. The vast majority of H3K18ac and H3K27ac peaks within each cell line overlapped, suggesting that 
enhancers in JIMT1 and SKBR3 cells contained both modifications (Fig. 2b). Enrichment of H3K18ac near the 
transcription start site (TSS) of all genes was similar between the cell lines, with peaks at −250 and +200 (Fig. 2c). 
Interestingly, SKBR3 cells contained higher enrichment of H3K27ac near the TSS of all genes, although the loca-
tions of the peaks were similar to the ones observed in the H3K18ac TSS profile (Fig. 2c).
The overall genomic locations of H3K18ac and H3K27ac were similar between JIMT1 and SKBR3 cells when 
divided into intergenic, promoter (<3 kb upstream from transcription start site TSS) and gene body regions 
(Fig. 2d). The majority of H3K18ac and H3K27ac peaks in both cell lines were located within gene bodies 
(Fig. 2d). We determined the transcription factor binding sites (TFBS) that were enriched near H3K18ac and 
H3K27ac peaks in both cell lines. Interestingly, the motif for LRF (ZBTB7A) was enriched in all four conditions. 
ZBTB7A, also known as LRF, was expressed in both cell lines well above the FPKM cutoff (Supplementary Fig. 3). 
All other enriched motifs were different in ChIP targets and cell lines. Lastly, hormone receptor motifs for proges-
terone and androgen receptors (PR and AR), were enriched near H3K27ac peaks in SKBR3 cells.
H3K18ac and H3K27ac at DEGs in JIMT1 and SKBR3 cells. To determine whether the most highly 
DEGs correlated with chromatin activation marks, we investigated H3K18ac and H3K27ac enrichment centered 
at the TSS of those genes. The top-250 DEGs in JIMT1 cells contained higher H3K18ac and H3K27ac levels in 
Sample Replicate 1 Replicate 2 Total reads Passed filters
JIMT1-H3K18ac 31686646 45386845 77073491 75496283
JIMT1-H3K27ac 32606409 28728176 61334585 60451093
JIMT1-H3K27me3 28596918 22941437 51538355 50687288
JIMT1-INPUT 31978471 43889876 75868347 74559927
SKBR3-H3K18ac 28338932 36517693 64856625 63772400
SKBR3-H3K27ac 40314271 23039795 63354066 62490689
SKBR3-H3K27me3 27815082 22296967 50112049 49198653
SKBR3-INPUT 21981986 31279741 53261727 52219799
Table 2. ChIP-seq reads of replicates. Reads reported from Illumina HiSeq3000 instrument for replicates and 
those passing default quality filters.
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JIMT1 (Fig. 3a). The top-250 DEGs in SKBR3 cells contained higher H3K18ac and H3K27ac in SKBR3, but the 
average tag density was vastly greater for H3K27ac throughout the −1000 to +1000 window (Fig. 3a). To gain 
some insight into putative activators that could be driving expression of the top-250 DEGs in each cell line, we 
determined the TFBS at the promoters (−300 to +50) of those genes. IRF8, IRF3 and SIX2 binding motifs were 
enriched in the top-DEGs in JIMT1 cells (Fig. 3b). MEF2a and HAND2 binding motifs were enriched in the 
top-DEGs in SKBR3 cells. IRF3 and SIX2 were more highly expressed in JIMT1 cells and MEF2a was more highly 
expressed in SKBR3 cells (Supplementary Fig. 4).
The most highly DEGs were UCHL1 and KRT81 in JIMT1 and SKBR cells, respectively (Supplementary data-
sets and Fig. 3c). A closer look at H3K18ac and H3K27ac near those genes, illustrates the findings discussed 
above, namely, higher enrichment of the modifications consistent with differential gene expression. H3K18ac 
Figure 2. H3K18ac and H3K27ac ChIP-seq and transcription factor binding sites (TFBS) near H3K18ac and 
H3K27ac. (a) Total H3K18ac and H3K27ac peaks in each condition and overlapping peaks between cell lines. 
(b) Comparison of H3K18ac and H3K27ac peaks within the same cell line. (c) H3K18ac and H3K27ac peaks at 
all TSS from −1000 to 1000 as reported by CEAS. (d) Locations of H3K18ac and H3K27ac peaks when broken 
down into three bins: intergenic, promoter (−3kb to TSS) and gene body (TSS to TTS). (e) Transcription 
factor binding sites (TFBS) query results as indicated by HOMER search. All motifs shown were enriched at 
p-value < 0.01 as reported by HOMER.
Figure 3. H3K18ac, H3K27ac and TFBS at DEGs. (a) H3K18ac and H3K27ac at top-50 DEGs in JIMT1 (top) 
and SKBR3 (bottom) as reported by CEAS. (b) TFBS query results as indicated by HOMER search. All motifs 
shown were enriched at p-value < 0.01 as reported by HOMER. (c) FPKM expression data juxtaposed to IGB 
ChIP H3K18ac and H3K27ac locus containing gene of interest. UCHL1 is the top DEG in JIMT1. KRT81 is the 
top DEG in SKBR3.
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and H3K27ac enrichment was higher in JIMT1 near the UCHL1 TSS compared to SKBR3 (Fig. 3c). H3K18ac 
and H3K27ac enrichment was higher in SKBR3 downstream of the KRT81 transcription termination site and 
throughout the gene body compared to JIMT1. We investigated H3K18ac and H3K27ac at other DEGs (ERBB2, 
CD44 and CD24). H3K18ac and H3K27ac enrichment near the loci of those DEGs was correlated to gene expres-
sion levels (Supplementary Fig. 5 and data not shown). Taken together, the ChIP-seq data suggests that the differ-
ential gene expression between JIMT1 and SKBR cells is determined at the level of chromatin regulation.
Additional DETs, DEGs and H3K27me3 enrichment in SKBR3 cells. Upon closer investigation 
of DETs and DEGs, we found that transcripts SUZ12, EED and EZH2 were significantly higher in JIMT1 cells 
(Fig. 4a). In addition, having previously identified WNT3 as an important molecule in trastuzumab resist-
ance9, we searched for WNTs that were DE in the data sets and identified WNT9A, WNT5B, and WNT7B as 
DEGs (Fig. 4a). We confirmed differential gene expression for EZH2, SUZ12, WNT5B and WNT9A by subject-
ing protein lysates from JIMT1 and SKBRB3 to immunoblot analysis (Fig. 4b-left and Supplementary Fig. 6). 
Interestingly, total H3K27me3 was also higher in JIMT1 cells (Fig. 4b). Wnt/β-catenin signaling has also been 
shown to play a significant role in both SKBR3 and BT474 cells acquiring resistance that was mainly due to 
upregulation of WNT39. Knockdown WNT9A by siRNA in JIMT1 showed enhanced JIMT1 cells’ response to 
trastuzumab. Upon trastuzumab treatment the cell viability was significantly reduced in the WNT9A knockdown 
cells compared to negative sequence treated cells (JIMT1-Scrambled) (Fig. 4b-right top). Furthermore, knock-
down of WNT9A, but not WNT5B in JIMT1 cells decreased EZH2 protein expression (Fig. 4b right-bottom). 
The data suggests a possible role of PRC2 complexes in trastuzumab resistance that may involve the Wnt signaling 
pathway. Nonetheless further proof of principle experiments are warranted to validate the involvement of PRC2 
in the epigenomic reprogramming of the resistant cells.
SUZ12, EED and EZH2 are components of the Polycomb Repressive Complex-2 (PRC2)20,21. PRC2 contains 
methyltransferase activity, through EZH2, that is responsible for depositing H3K27me3 marks. This modification 
results in the silencing of chromatin by promoting condensation of the locus20. Given the higher expression of 
SUZ12, EED and EZH2 and the higher levels of H3K27me3 in JIMT1, we investigated H3K27me3 by ChIP-seq 
Figure 4. WNTs, PRC2 components, and H3K27me3 enrichment in SKBR3 cells. (a) FPKM data for WNTs 
and PRC2 components in JIMT1 and SKBR3 cells. P-value reported is from Cufflinks output data. (b-right) 
Western blot data comparing whole cell lysates from JIMT1 and SKBR3 cells (n = 2). Western blots utilized 
same lysates and same gels in most cases, unless samples were overloaded in which case they were rerun with 
less protein (see Supplementary Fig. 7 for more complete images); (b-left top) JIMT1 cells were plated in 96 
well plate at 5000 cells/per well and treated with scrambled RNA or siRNA WNT9A for 72 hours. Trastuzumab 
was added after 24 hours siRNA treatment for 3 days. MTT assay was used for evaluated cell growth. Each data 
point was 6 measurements and the graph showed mean of 6 measurements plus standard deviation, **p < 0.01 
compared to untreated cells; (b-right bottom). JIMT1 cells were treated with pooled of two siRNA-sequences 
against WNT9A (siWNT9A), WNT5B (siWNT5B) or negative sequences (control) for 72 hours and total 
protein was extracted followed by Western Blot with antibody against WNT9A, WNT5B and EZH2. GAPDH 
was used as loading control. (c) FPKM data for top DEGs in JIMT1, FOXD1, ITGA6, and SERPINE1, in JIMT1 
and SKBR3 cells. P-value reported is from Cufflinks output data. (d) IGB screenshots for genes contained in (c) 
containing tracks for H3K18ac, H3K27ac and H3K27me3.
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in JIMT1 and SKBR3 cells (Table 2 and Fig. 4). Surprisingly, inspection of various loci that contained DEGs 
(FOXD1, ITGA6, SERPINE1 and SIX2) with higher expression in JIMT1 cells, revealed extensive H3K27me3 near 
or in the coding region in SKBR3 cells but absent in JIMT1 cells (Fig. 4c,d and Supplementary Fig. 7). A locus 
with several KRT genes contained noticeable H3K18ac and H3K27ac peaks but low H3K27me3 peaks in JIMT1 
cells. On the other hand, the same region, contained low H3K18ac and H3K27ac, but high H3K27me3 peaks in 
SKBR3 cells (Supplementary Fig. 7).
H3K18ac and H3K27ac and Trastuzumab resistance. The higher levels of FOXD1, ITGA6, SERPINE1 
and SIX2 in JIMT1 were confirmed by RT-qPCR (Fig. 5a-left panel). To further understand if the higher levels 
of those genes are associated with trastuzumab resistance, we examined the levels of those genes in another tras-
tuzumab resistant cell line SKBR3/100-8. The SKBR3/100-8 cell line was generated from SKBR3 though clonal 
selection under trastuzumab exposure9. The data showed that the levels of FOXD1, ITGA6 and SERPINE1 were 
significantly higher in SKBR3/100-8 compared to parental SKBR3 cells (Fig. 5a-right panel). However, the level 
of SIX2 was lower in SKBR3/100-8 compared to SKBR3 (Fig. 5.-right panel). A-485, a selective small-molecule 
inhibitor of P300/CBP acetylase activity has been shown to decrease H3K18ac and H3K27ac, but not H3K9ac, 
in prostate cancer cells22. Our data showed that A-485 reduced H3K18ac and H3K27ac in JIMT1 cells (Fig. 5b). 
The levels of FOXD1, ITGA6, SERPINE1 and SIX2 in JIMT1 were reduced significantly following treatment with 
A-485 (Fig. 5c left-panel). ITGA6 and SIX2 have been indicated promoting EMT (Epithelial-to-mesenchymal 
transition)23,24 and cells undergoing EMT have been shown to be increasingly resistant to trastuzumab9,25,26. We 
found in this study that EMT markers, TWIST, SNAIL and SLUG were also reduced following treatment of JIMT1 
cells with A-485 (Fig. 5c right-panel). Moreover, inhibition of P300/CBP in JIMT1 cells reduced cell viability, and 
the cells showed sensitivity to trastuzumab once treated with a combination of trastuzumab and A-485 (Fig. 5d).
Discussion
Utilizing NGS methods we conducted a transcriptomic and ChIP-seq based comparison between a trastuzumab 
sensitive (SKBR3) and resistant (JIMT1) cell line. We determined that there were ~3200 DEGs and ~2800 DETs 
that were statistically significant (p-value < 0.05) between JIMT1 and SKBR3 cells (Fig. 1a). This greatly expands 
the number of DEGs and DETs ever reported between JIMT1 and SKBR3 cells12,13. As an example, there are eight 
CD44 transcripts annotated in hg19, three of these were expressed higher than 2-fold in JIMT1 cells compared to 
Figure 5. Inhibition of P300/CBP acetylase activity reduces EMT and enhances inhibitory effectiveness of 
trastuzumab. (a) mRNA levels of FOXD1, ITGA6, SERPINE1 and SIX2 were examined by RT-qPCR. The bars 
indicated mean of three values plus stander deviation. The levels of each indicated genes in SKBR3 were used 
as references and all levels were adjusted for 18S, *p < 0.05 and **p < 0.01 compared to the levels in SKBR3. 
(b) JIMT1 cells were treated with A-485 for 24 hours and Western blot data comparing whole cell lysates from 
the A-485 treated and no-treated cells. Antibodies for H3K27ac, H3K18ac, total H3 and GAPDH were used 
for detecting effect of A-485 in protein levels of H3K27ac and H3K18ac. Total H3 and GAPDH were used as 
loading control. (c) JIMT1 cells were treated with 10 µ of A-485 for 24 hours and mRNA levels of the indicated 
genes were determined by RT-qPCR. The bars indicated mean of three values plus stander deviation. The levels 
of each indicated genes in untreated cells were used as references and all levels were adjusted for 18S. **p < 0.01 
compared to untreated cells. (d) JIMT1 cells were plated in 96 well plate at 5000 cells/per well and treated with 
(1) 10 µ of A-485, (2) 40 µg trastuzumab, (3) A-485+ trastuzumab, (4) untreated (control) for 72 hours. MTT 
assay was used for evaluated cell viability. Each data point was 6 measurements and the graph showed mean of 6 
measurements plus standard deviation, **p < 0.01 compared to untreated cells.
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SKBR3 cells (Fig. 1b). However, only one of these three (NM_001001389) was statistically significant due to the 
variance in the replicates and the limited amount of replicates (n = 2) (data not shown).
By conducting GO analysis of the top-50 DEGs in both cell lines, we determined that the top DEGs in JIMT1 
are involved in motility and migration (Fig. 1c). This is consistent with previously published reports that migra-
tory cells, specifically those undergoing Epithelial Mesenchymal Transition (EMT), are more resistant to trastu-
zumab25,27. The most highly DEG was UCHL1, expressed over 300-fold higher in JIMT1 cells (Fig. 3c). UCHL1 
(Ubiquitin C-terminal hydrolase-L1) has previously been shown to reverse ubiquitylation of HIF-1α and pro-
mote metastasis in a HIF-1-dependent manner28. Furthermore, overexpression of UCHL1 is consistent with a 
multi-drug resistance (MDR) phenotype in breast cancer cells and is believed to function through EGFR and 
MAPK29,30. A thorough proteomic investigation could be useful in identifying novel UCHL1 targets that promote 
HER2+ breast cancer metastasis.
Another interesting DEG that was among the top-50 DEG was SIX2 (Supplementary Fig. 4). SIX2 is a member 
of the Sineoculis homeobox homolog family of proteins. All six of the SIX family members have been implicated 
in breast cancer and SIX2 is upregulated in basal-like breast cancer31. SIX2 promotes metastasis by repressing 
E-cadherin expression and has also been demonstrated to promote maintenance of a stem cell niche in nephrons 
through its interaction with TCF/LEF/β-catenin24,32. Interestingly, in our data, the SIX2 binding motif was among 
the most highly enriched in the top-DEGs expressed in JIMT1 cells (Fig. 3b). However, confirmation study 
showed a lower level of SIX2 in acquired resistant cells SKBR3/100-8 (Fig. 5a).
We previously identified WNT3 as a molecule that contributed to the development of trastuzumab resistance9. 
Although WNT3 was expressed over 2-fold higher in JIMT1 cells compared to SKBR3 cells, the FPKM for WNT3 
in SKBR3 was <0.5 and therefore did not make our cutoff (data not shown). However, two other WNTs, WNT5B 
and WNT9a, were expressed 32-fold and 5-fold higher, respectively, in JIMT1 cells. (Fig. 4a,b). Knockdown of 
WNT9a decreased EZH2 and sensitized JIMT1 cells response to trastuzumab (Fig. 4b), suggesting a possible role 
of PRC2 complexes in trastuzumab resistance and involving Wnt signaling pathway. In this study WNT5B made 
the top-50 DEG list that was utilized in the determination of GO (Fig. 1c). Although WNT5B has been classified 
as a non-canonical WNT, it activated the canonical WNT pathway in triple negative breast cancer (TNBC) cells33. 
In this context, knockdown of WNT5B resulted in decreased cell growth, migration and mammosphere forma-
tion. Therefore, WNT5B might also promote trastuzumab resistance and CSC maintenance.
Three Annexin genes, ANXA1, ANXA8L1 and ANXA8L2, were among the top-50 DEGs in JIMT1. ANXA1 
was recently described as a strong predictor of trastuzumab resistance, primarily through its activation of AKT 
signaling, and has also been shown to promote cellular invasion in TNBC cells34,35. However, in the previous 
findings, high ANXA1 levels were partially dependent on decreased ARID1A expression. In our data set ARID1A 
levels were comparable in JIMT1 and SKBR3 cells (data not shown). There is scant literature on ANXAL1 and 
ANXAL2, especially on how they might relate to oncological phenotypes. More investigations on the highly DE 
Annexin genes and their function will need to be conducted. Lastly, one of the main transcription factors involved 
in activating EMT genes, SLUG (SNAI2), was expressed much higher in JIMT1 compared to SKBR3 (as has pre-
viously been reported23) but was excluded from our analysis because the FPKM < 0.5 in SKBR3 cells.
Utilizing ChIP-seq we compared H3K18ac and H3K27ac in JIMT1 and SKBR cells. JIMT1 and SKBR3 cells 
shared less than 50% of H3K18ac and H3K27ac peaks, indicating different chromatin landscapes (Fig. 2a). It 
is likely that overlapping peaks occurred over LRF motifs, given the presence of the LRF motif in all the ChIPs 
(Fig. 2e). LRF (ZBTB7A) is an oncogenic transcription factor that is induced by TGF-β1 and is aberrantly 
expressed in breast cancer tissue36,37. A genome-wide analysis of LRF binding has yet to be conducted in HER2+ 
breast cancer cells. Such an investigation could determine the transcriptional targets of LRF. The remaining top 
transcription factor binding motifs were different in all conditions, possibly explaining the non-overlapping 
H3K18ac and H3K27ac peaks (Fig. 2a,e). H3K18ac and H327ac peaks demonstrated significant overlap in each 
cell line, consistent with the modifications being co-enriched at regulatory regions (Fig. 2b). Taken together, our 
ChIP-seq data suggests that similar H3K18ac and H3K27ac peaks between JIMT1 and SKBR3 are regulated by 
LRF recruitment of P300/CBP and dissimilar peaks are regulated by the recruitment of P300/CBP to those sites 
by various other activators.
By focusing on top-DEGs in each cell line we clearly observed that H3K18ac and H3K27ac enrichment 
strongly corresponded with expression data (Fig. 3a). UCHL1 was the most highly DEG in JIMT1 cells and its 
expression was consistent with H3K18ac and H3K27ac enrichment near the 5′ end of UCHL1 (Fig. 3c). On the 
other hand, KRT81 was the most highly DEG in SKBR3 cells and the KRT81 gene body contained noticeable lev-
els of H3K18ac and H3K27ac that were absent in JIMT1 cells. The transcription factor binding motifs that were 
enriched in the top-DEGs in each cell line suggest that IRF8/IRF3/SIX2 are putative drivers of DEGs in JIMT1 
cells. Nonetheless, only IRF3 and SIX2 levels, and not IRF8, were detectable by RNA-seq (Supplementary Fig. 4). 
However, the upregulation of IRF3 and SIX2 were only confirmed in JIMT1 cells. The SIX2 level was lower in 
SKBR3/100-8 compared to SKBR3 and IRF3 level was similar between SKBR3/100-8 and SKBR3 cells. We will 
have to conduct follow-up experiments to determine IRF3 and SIX2 protein levels and their role in activating 
transcriptional targets in JIMT1 cells.
The higher levels of components of PRC2, SUZ12, EED and EZH2 (Fig. 4a,b and Supplementary Fig. 6), in 
JIMT1 cells prompted us to investigate H3K27me3 by ChIP-seq. There were ~5 fold more H3K27me3 peaks 
in JIMT1 cells than in SKBR3 cells (data not shown) and this was reflected in western blot analysis (Fig. 4b). 
Surprisingly, top DEGs, like FOXD1, ITGA6 and SERPINE1, in JIMT1 cells contained low levels of H3K27me3 
but high levels in SKBR3 cells (Fig. 4c,d). There are conflicting reports about the role and clinical implications 
of PRC2 and H3K27me3 levels in breast cancer. High PRC2 levels were observed in TNBC and HER2+ tumors 
and breast cancer cells38. However, H3K27me3 levels were highest in luminal A tumors and not in TNBC and 
HER2+ tumors. In another study, low levels of PRC2 were found to correlate with poor prognosis39. Nonetheless 
our data in this study showed that downregulation of EZH2, due to WNT9a knockdown, sensitized JIMT1 cells 
8Scientific RepoRts |          (2019) 9:5141  | https://doi.org/10.1038/s41598-019-41672-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
to trastuzumab, suggesting that the WNT signaling pathway might play a role in regulation of EZH2 and tras-
tuzumab resistance (Fig. 5a,b). However, further functional studies are required to understand the mechanisms 
and to validate the involvement of PRC2 in the epigenomic reprogramming of the resistant cells. We plan to 
determine the role of PRC2 in trastuzumab resistance and breast cancer metastasis.
In addition our study further confirmed that high levels of FOXD1, ITGA6 and SERPINE1 were associated 
with HER2-overexpressing breast cancer cells resistant to trastuzumab (Fig. 5a) and they were regulated by 
acetylation of H3K27 and H3K18 (Fig. 5b,c). Inhibition of P300/CBP acetylase activity promoted responsiveness 
to trastuzumab and this may be due to the downregulation of FOXD1, ITGA6 and SERPINE1 and inhibition of 
EMT (Fig. 5c,d).
In summary, we propose a model (Fig. 6) Where-upon top-DEGs in JIMT1 are activated by IRF3/SIX2 result-
ing in recruitment of P300/CBP and subsequent deposition of H3K18ac and H3K27ac marks. This fails to occur 
in SKBR3 cells because they (1) express lower levels of IRF3 and SIX2 and (2) the detection of H3K27me3 near 
their coding region. Further studies will need to be conducted to test the various characteristics of our model. 
This includes an investigation of the function of PRC2 in JIMT1 and SKBR3 cells, the genes that are silenced by 
PRC2 and whether trastuzumab resistance can be overcome by compromising PRC2 function.
Methods
RNA-seq. JIMT1 and SKBR3 cells were grown to sub-confluent density. RNA was isolated using Trizol 
(ThermoFisher Scientific, catalog number 15596026). Nanodrop and Qubit Fluorometric instruments were used 
to determine RNA concentrations. 1 ug of RNA was used to construct libraries with KAPA mRNA Hyperprep Kit 
(Roche KK8580). Libraries were sequenced on an Illumina Hiseq3000 instrument.
RNA-seq analysis. Single end 50 bp mRNA-seq reads were aligned to hg19 using default parameters of 
Tophat2 (version 2.1.0) and Bowtie2 (version 2.3.2). Samtools (version 0.1.18) was used to convert SAM to BAM 
files. FPKM values were generated using default parameters for Cufflinks (version 2.1.1). Only FPKM values 
greater than 0.5 were considered for further analysis. Cufflinks output statistical analysis was utilized to determine 
significance.
ChIP-seq. JIMT1 and SKBR3 cells were grown to sub-confluent density. Formaldehyde was added to a final 
concentration of 1% and incubated for 10 min at 37 °C. Following PBS washing, cells were scraped and washed 
with 1 mL of PBS containing protease inhibitors (Roche). Cells were resuspended in lysis buffer at a ratio of 
5 × 106 cells per 100 ul of lysis buffer. 150 ul of cell lysate was used in chromatin immunoprecipitation with a 
given antibody. 10 ul of cell lysate was saved for use as input. 3 ug of antibody (H3K18ac (EMD Millipore, catalog 
07-354), H3K27ac (Active Motif, catalog 39135) and H3K27me3 (Active Motif, catalog 39155)) was used per 
ChIP. Following washes and elution, immunoprecipitated material was reverse crosslinked overnight at 65 °C. 
Samples were treated with RNase A for 30 min at 37 °C and then with Proteinase K for 2 hrs. at 56 °C. DNA was 
recovered using phenol/chloroform extraction and precipitation. Qubit Fluorometric instrument was used to 
quantify concentration of recovered DNA. 1 ng of DNA was used to construct libraries with KAPA Hyper Prep 
Kit (Roche KK8502). Libraries were sequenced on an Illumina Hiseq3000 instrument.
ChIP-seq analysis. Single end 50 bp reads were aligned to hg19 using default parameters of Bowtie2 (version 
2.3.2). Only reads that aligned to a unique position in the genome with no more than two sequence mismatches 
were retained for further analysis. Peaks were identified with MACS2 (version 2.1.1) using default parameters 
(p-value < 0.0005). MACS2 output Bedgraph files were converted to BigWig using bedGraphtoBigWig. Next, 
Bigwig files were converted to Wiggle files for use in CEAS with bigWigtoWig (http://hgdownload.soe.ucsc.
edu). Integrated Genome Browser (IGB) was used to view Bedgraph, Bigwig and Wiggle files (http://bioviz.org/
igb/). Average H3K18ac and H3K27ac enrichment near the TSS was determined using Cis-regulatory Element 
Annotation System (CEAS) (http://liulab.dfci.harvard.edu/CEAS/). Bedtools (version 2.26.0) intersect option was 
used to determine overlapping peaks between H3K18ac or H3K27ac peaks at different time points.
Figure 6. Regulation of gene expression in JIMT1 and SKBR3 cells. IRF/SIX2 motifs were enriched in top-
DEGs in JIMT1. These genes contained high levels of H3K18ac and H3K27ac. JIMT1 cells contained low levels 
of H3K27me3 at these genes. SKBR3 cells contained low levels of H3K18ac and H3K27ac at the same genes. 
SKBR3 cells contained high levels of H3K27me3 at these genes.
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Transcription factor binding site (TFBS) query. Homer (version 4.9) (homer.ucsd.edu) was used to find 
enriched motifs from −300 to +50 bp (default settings) of each cluster in the RNA-seq data set. Only motifs that 
were enriched with a p-value < 0.01 are reported.
Gene Set Enrichment Analysis (GSEA). Version 3.0 (http://www.broadinstitute.org/gsea/) was used to 
conduct GSEA (Broad Institute at MIT, Cambridge, MA) on all DEGs between JIMT1 and SKBR3 cells. GCT and 
respective CLS file were generated using the FPKM_trackingToGct and ClsFileCreator modules on Genepattern 
(http://genepattern.broadinstitut.org), respectively. A 2-class analysis with 1000 permutations of gene sets and a 
weighted metric was used. Given our low number of samples, we utilized the log2 ratio of classes as our metric 
for ranking genes. Each replicate was considered a different sample (i.e 2 samples per condition (“SKBR3” or 
“JIMT1”). A false discovery rate (FDR) < 0.05 was considered significant.
Western blot. Protein lysates were prepared using EBC modified buffer (50 mM Tris-Cl (pH 8.0), 150 mM 
NaCl, 0.5% NP-40) containing Thermo Scientific Protease and Phosphatase Inhibitor Tablets (A32959). The 
following antibodies were used: WNT5B (GeneTex, Cat. GTX47174), WNT9A (GeneTex, Cat. GTX128110), 
EZH2 (Cell Signaling Technology, Cat. 5246S), SUZ12 (Cell Signaling Technology, Cat. 3737), H3 (Cell Signaling 
Technology, Cat. 5192S) and β-actin (Santa Cruz Biotechnology, sc-69875).
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